title: [New oral anticoagulants - influence on coagulation tests].
abstract: The new oral anticoagulants (NOACs) represent alternative antithrombotic agents for prophylaxis and therapy of thromboembolic diseases. They act either by inhibition of the clotting factor Xa or IIa (thrombin). As a consequence, they influence several coagulation assays (for example prothrombin time, activated partial thromboplastin time). Because of the short half-life of these new agents, these changes show great variations in the course of 24 hours. Furthermore, there are significant differences of laboratory results depending on the used reagents. We explain the influence of apixaban, rivaroxaban (factor Xa inhibitors) and dabigatran (thrombin inhibitor) on the most commonly used coagulation assays. Besides we show that this influence depends on the way of action of the drug as well as on the principle of the coagulation assay. Being aware of this relationships helps to interpret the results of coagulation assays under influence of NOACs correctly.
authors.affiliation: Abteilung für Hämatologie und Hämatologisches Zentrallabor, Luzerner Kantonsspital, Schweiz.
authors.forename: L
authors.initials: L
authors.lastname: Simeon
authors.affiliation: Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor, Inselspital, Bern, Schweiz.
authors.forename: M
authors.initials: M
authors.lastname: Nagler
authors.affiliation: Abteilung für Hämatologie und Hämatologisches Zentrallabor, Luzerner Kantonsspital, Schweiz.
authors.forename: W A
authors.initials: WA
authors.lastname: Wuillemin
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects* / Q000493:pharmacokinetics; D000941:Antigens; D001780:Blood Coagulation Tests; D004305:Dose-Response Relationship, Drug; D065427:Factor Xa Inhibitors; D006474:Hemorrhagic Disorders / Q000097:blood / Q000139:chemically induced; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D011516:Prothrombin / Q000037:antagonists & inhibitors; D012307:Risk Factors; D013923:Thromboembolism / Q000097:blood* / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D000941:Antigens; D065427:Factor Xa Inhibitors; C055042:factor II clotting antigen; D011516:Prothrombin